NEWS&VIEWS 25 Telstar Takes a Major Step into the French Market


The Telstar Group has acquired French company Usifroid which is internationally recognized for the development and supply of GMP lyophilisers for the pharmaceutical markets and for pioneering the use of liquid nitrogen (LN2) refrigeration technology in freeze drying.


This acquisition reinforces Telstar’s position in the international life sciences market and consolidates its position in Europe with a French market share of 80% in freeze drying equipment solutions for the pharmaceutical industry.


Within the Telstar Group, the Usifroid brand and product range will be retained in all markets. Jordi Puig, Corporate Business


Director of Telstar Life Sciences said: “The incorporation of Usifroid into the Telstar Group equates not only to expansion of our activities internationally, but also adds new know-how and expertise in the freeze drying field and helps consolidate our position in the European market by having an operations and services in France.”


“Joining the Telstar group brings to Usifroid not only the support it has always needed to develop its activities but also the understanding and experience of a group which knows the requirements of excellence needed by an equipment business dedicated to the life sciences market.” said Benoit d’Armancourt, General Manager of Usifroid.


Acquisition of Starlims Completed


Abbott has completed its $123 million acquisition of STARLIMS Technologies Ltd., a leader in laboratory information management systems.


The acquisition provides Abbott with leading products and expertise to build its position in laboratory informatics, an emerging and rapidly growing field focused on helping to manage the increasing amount of data generated in laboratories. Starlims’s advanced web-based software applications help laboratories efficiently store, retrieve and analyse data and are designed for a wide variety of laboratory


environments operating across a number of scientific, industrial and clinical disciplines.


"Starlims gives us access to innovative technologies and technical expertise for our long-term strategy in laboratory informatics," said Edward L. Michael, executive vice president, diagnostics products, Abbott. “The acquisition enables us to provide a common informatics framework across all of our diagnostics businesses and, equally important, will help accelerate Starlims’s growth strategy in the non-diagnostics market segments it currently serves.”


TO FIND OUT MORE CIRCLE NO.


PANalytical and Sodern Analysers Alliance


Leading analytical X-ray company PANalytical (Almelo, the Netherlands) has entered a strategic alliance with neutron generator based analyser specialist SODERN (Limeil-Brevannes, France), for worldwide distribution and support of SODERN’s neutron based cross-belt analysers.


Guido Eggermont, Commercial Director, PANalytical, said: “Bringing SODERN’s exciting switchable neutron source technology into our portfolio is a significant move. It will widen the solutions we can provide to our customers in the cement, minerals and coal sectors. PANalytical has a great tradition in these industries and our


reputation for the combination of cutting-edge technology with ultimate commitment in support and safety can only be enhanced by this new development.”


“Leveraging our unique Pulsed Fast and Thermal Neutron Analysis (PFTNA) technology with the worldwide commercial footprint of PANalytical will ensure our customers benefit from unparalleled expertise and customer support.” said Franck Poirrier, CEO of SODERN. “It will also facilitate further development of this technology into new applications and markets,” he added.


TO FIND OUT MORE CIRCLE NO. 67 65


LGC Establishes Genomics Division


LGC, a leading independent provider of diagnostic and analytical testing services and reference materials to the public and private sectors, announced the launch of its Genomics division this month.


Jordi Puig Corporate Business Director, Telstar Life Sciences


TO FIND OUT MORE CIRCLE NO.


SphereOptics Acquired by Halma


Halma Plc, a leading safety, health and sensor technology group (United Kingdom), has acquired SphereOptics, a maker of custom light measurement technologies. SphereOptics will join Halma’s global group of photonics businesses as it is merged with light metrology industry leader Labsphere.


Based in New Hampshire, USA, SphereOptics manufactures and distributes custom radiometric and photometric products to address the specific needs of the aerospace, automotive, electronic imaging, laser diode, LED, lighting, medical imaging and optics industries. Also based in New Hampshire, Labsphere products include LED, laser and traditional light source light measurement systems; uniform light sources for imaging device calibration; spectroscopy accessories; and high diffuse reflectance materials and coatings for applications in backlit panel displays, computed radiography, and system calibration. “The reunion of two industry leaders, Labsphere and SphereOptics, will provide our customers with innovative, high quality products, world class technical expertise and unequalled customer service," commented Labsphere President Kevin Chittim


TO FIND OUT MORE CIRCLE NO.


Technical Guide for US FDA-Regulated Organisations Proper FDA 483 letter response is


Technical Guide for US FDA-Regulated Organisations FDA 483 letters are expected to increase this year, reflecting the FDA’s recent staff expansion and rewrite of the FDA 483 Letter rules to narrow response time to the new 15-day window. This has bearing both for US-headquartered laboratories and international laboratories involved in making FDA-regulated products sold in the US.


Now Veriteq, a leader in FDA-compliant environmental monitoring, alarming, reporting and temperature/humidity technology offers a 10-step Guide to help the wide range of pharmaceutical processors, blood and tissue banks, clinical laboratories, medical device manufacturers, research hospitals, and other GxP facilities who may receive public criticism warning letters respond quickly and


appropriately within the permitted 15-day window.


critical to both help in reputation repair and for real remediation actions to assure a quality process and patient safety.


Ken Appel, Veriteq Vice President Regulated Markets, commented: "Veriteq is keenly aware of the great number of FDA-regulated companies that thought they were in full compliance but were not when it came to temperature monitoring. Since Veriteq offers the only monitoring system that ensures both gap-free records and accuracy in between calibration intervals we have always had customers who came to Veriteq because they were using inferior solutions. Customers are often disappointed over the failure of chart recorders or data loggers to record data


68 64


Since acquiring Berlin-based AGOWA GmbH in 2005, genomics has seen successful growth as part of LGC’s Life & Food Sciences Division, providing an array of flexible nucleic acid sample extraction services and products such as DNA sequencing, next generation sequencing and genomic services to international pharmaceutical and biotechnology companies and private and public research organisations. The launch of the new division is part of a wider organisational restructuring and is in line with LGC’s strategy for growth and expansion of operations. As part of the restructuring process, AGOWA genomics products and services will be rebranded LGC Genomics.


The international DNA sequencing and genomics market is experiencing rapid growth. The decision to launch the LGC Genomics division reflects LGC’s confidence in its ability to expand its range of products and services and continue to invest in its staff, facilities and equipment..


John McQuillian, Managing Director of the LGC Genomics Division, commented: “The launch of LGC Genomics as a new operating division is an exciting step for LGC and presents excellent opportunities for growth. Under the new brand, LGC Genomics will continue to advance the development and delivery of first-rate genomic services and products, keeping our customers at the forefront of technology and expertise in this increasingly sophisticated field of science. Our aim is for LGC Genomics to become Europe's leading genomics provider, through organic growth and selected strategic acquisitions.”


TO FIND OUT MORE CIRCLE NO.


Partnership to offer ChIP-Seq Solutions


during facility power outages, hold calibration accuracy of sensors or other equipment failure that had triggered negative FDA actions or product loss. If and when a company receives a Warning Letter it is a matter of public record listed on the FDA's web site. Veriteq's guide- ’How to Avoid and Respond to Public FDA Criticisms-Form 483 Letters-for Temperature, Humidity and other Controlled Environments’ will help quality departments that have received such public criticism regroup, but more importantly, will give some best-practice tips that will help FDA-regulated organisations avoid Warning Letters in the first place."


For further details visit: www.veriteq.com/fda_response.htm or contact: Janice Bennett, Tel: +1-604-273-6850


TO FIND OUT MORE CIRCLE NO. 69


Beckman Coulter Genomics, Inc and Genpathway, Inc are offering whole-genome chromatin immunoprecipitation sequencing (ChIP-Seq) services supporting genome-wide studies of transcription factor binding, gene transcription and epigenetic events.


ChIP-Seq combines chromatin immuno- precipitation with ultra high-throughput next generation DNA sequencing to enable the study of complex interactions between proteins and nucleic acids. Mapping protein- DNA complexes in vivo builds a picture of the intricate network of interactions that regulate genes and genetic pathways in a sample. Comparing ChIP-Seq results from different conditions – diseased versus normal cells, for example – can reveal distinguishing patterns of genetic regulation that may be biologically significant.


TO FIND OUT MORE CIRCLE NO. 70 66


READ ALL THE LATEST NEWS & VIEWS, ARTICLES AND NEW PRODUCT RELEASES ONLINE, VISIT: WWW.LABMATE-ONLINE.COM


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68